GET DAILY SIGNALSAfya Limited (AFYA) Earnings Preview: What to Watch in the Q3 2026 Report
Key Takeaways
- Afya Limited is scheduled to report its third-quarter 2026 results after the U.S. market close on Thursday, November 12, 2026, followed by a conference call at 5:00 p.m. ET.
- Wall Street consensus calls for earnings per share (EPS) near $0.37 and revenue of roughly $190 million, with individual analyst estimates ranging from $0.36 to $0.39 for EPS.
- The company reports in Brazilian reais (BRL); most dollar-denominated consensus figures reflect currency translation and should be read alongside Afya's BRL-based results.
- In the prior quarter (Q2 2026), Afya beat EPS expectations ($0.43 vs. $0.40 consensus) but missed on revenue ($187.8 million vs. $189.6 million expected).
- Investors will focus on medical student intake trends, approved medical seat counts, and margin performance across Afya's three business segments.
- For more on the company's latest developments, visit Afya's Major News, Today's Price Move, Price Targets, and Forecast pages.
- Explore AI-driven trading strategies and market signals with Tickeron's Trending AI Robots.
Earnings Context and Why It Matters
Afya is Brazil's largest integrated medical education and digital health platform, spanning undergraduate medical schools, continuing education, and medical practice solutions. Its third-quarter 2026 report matters because it offers a fresh read on demand for medical education in Brazil and on the company's ability to sustain its multi-year growth and margin track record. Afya closed 2025 with revenue up 12% year over year and a seventh consecutive year of meeting or exceeding guidance, giving investors high expectations for consistency. The Q3 print will also test how new investment in its continuing education and medical practice solutions segments is affecting profitability, a key concern after management guided to a slightly lower margin in 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect AFYA to post EPS near $0.37 for the third quarter of 2026, with revenue projected at approximately $190 million. Estimates vary modestly by source: some analysts model EPS as low as $0.36, while others project $0.39, reflecting differing assumptions about currency translation and segment growth. For comparison, Afya reported EPS of about $0.39 on revenue of roughly $174 million in the year-ago quarter (Q3 2025).
In its most recent report, Q2 2026, Afya delivered EPS of $0.43—topping the $0.40 consensus—but revenue of $187.8 million came in slightly below the $189.6 million analysts had expected. That mixed result underscores why this quarter's revenue line, not just the bottom line, will be closely watched.
Key metrics beyond headline EPS and revenue include medical student enrollment (which exceeded 25,000 at year-end 2025), the number of approved medical school seats (3,755 at the end of 2025), and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin, which reached 45.4% in 2025 but is expected to moderate in 2026 as the company reinvests in its ecosystem.
Market Reaction and Investor Sentiment
Sentiment heading into the Q3 2026 report is cautious. Afya shares have traded well below their 52-week high, and the stock has declined more than 25% over the past year, even as the company has continued to deliver steady operational growth. The consensus analyst rating is a "Hold," with an average price target near $15.70, though recent actions have been mixed—one major bank trimmed its price target while maintaining an overweight rating, and another upgraded the stock to buy while lowering its target. This divergence reflects uncertainty about near-term revenue growth and margin pressure rather than any crisis in the underlying business. A revenue beat, particularly in the higher-margin undergraduate segment, would likely be viewed favorably, while another top-line miss could reinforce concerns about the pace of expansion.
Forward Outlook and Key Factors to Monitor
After this earnings event, investors should watch several forward-looking signals. First, management's full-year 2026 guidance—which currently calls for revenue between roughly $750 million and $779 million—will indicate whether the company remains on track for another year of growth. Any update on the margin trajectory will matter as well, since Afya has signaled it will reinvest in its continuing education and medical practice solutions segments during 2026.
Second, medical seat authorizations remain a structural growth driver. Afya ended 2025 with 3,755 approved medical school seats, and additional regulatory approvals from Brazil's Ministry of Education (MEC) can expand capacity and revenue over time. Progress on the student intake cycle for the second half of 2026 will be a key topic on the conference call.
Third, currency dynamics are worth monitoring. Because Afya reports in Brazilian reais, movements in the BRL/U.S. dollar exchange rate can meaningfully shift dollar-denominated results even when local-currency performance is stable. Finally, capital allocation—including the ongoing share repurchase program and dividend policy—will remain in focus as investors weigh the balance between reinvestment and shareholder returns.
Using AI Tools in My Research Process
From what I see, tools like Tickeron's AI Screener help streamline the process of comparing earnings setups across peers and spotting patterns in sector data. I often run quick scans on education and healthcare names to contextualize results like Afya's, which saves time when preparing for events like this earnings release. It integrates technical and fundamental filters in one place, making it straightforward to cross-check ideas without manual effort.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AFYA in downward trend: 10-day moving average broke below 50-day moving average on October 28, 2026
The 10-day moving average for AFYA crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AFYA as a result. In 60 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for AFYA turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 31 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
AFYA moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AFYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for AFYA entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AFYA's RSI Oscillator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 54 cases where AFYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where AFYA advanced for three days, in 214 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
AFYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. AFYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.190) is normal, around the industry mean (1.158). P/E Ratio (1.203) is within average values for comparable stocks, (8.484). AFYA's Projected Growth (PEG Ratio) (5.160) is very high in comparison to the industry average of (1.327). Dividend Yield (0.500) settles around the average of (4.151) among similar stocks. P/S Ratio (1.661) is also within normal values, averaging (27.566).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AFYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical education group in Brazil, which delivers an end-to-end physician-centric ecosystem that serves and empowers students to be lifelong medical learners through their medical residency preparation, post-graduate programs and continuing medical education activities
Industry OtherConsumerSpecialties
Advertisement